Under China's new medical reform, the government has become the largest purchaser of medicine. For pharmaceutical enterprises, favourable policies are the key to market access.
- All
- AI and Emerging Technology Integration
- Aviation
- Capital Markets
- Company News
- Consumer Brands
- Content Strategy
- Corporate Communications
- Crisis and Issues Communications Management
- Digital Communications
- Education
- Energy and Environment
- Financial
- Government and Public affairs
- Health
- International media
- Media Relations
- Multimedia Design and Production
- Primary Industries
- Professional Services
- Property and Infrastructure
- Public Relations
- Research
- Strategy
- Technology
- Travel and Hospitality
As countries progress beyond the COVID-19 era, we must not neglect other health issues such as antimicrobial resistance which could...
- All
- AI and Emerging Technology Integration
- Aviation
- Capital Markets
- Company News
- Consumer Brands
- Content Strategy
- Corporate Communications
- Crisis and Issues Communications Management
- Digital Communications
- Education
- Energy and Environment
- Environmental, Social and Governance (ESG)
- Financial
- Government and Public affairs
- Health
- International media
- Media Relations
- Multimedia Design and Production
- Primary Industries
- Professional Services
- Property and Infrastructure
- Public Relations
- Research
- Strategy
- Technology
- Travel and Hospitality
Under China's new medical reform, the government has become the largest purchaser of medicine. For pharmaceutical enterprises, favourable policies are the key to market access.
As countries progress beyond the COVID-19 era, we must not neglect other health issues such as antimicrobial resistance which could...